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1. Introduction    
Microglia, the resident immune cells of the central nervous system (CNS), are responsible 
for the innate brain immune defence. The exact origin of microglia is still unclear, but 
several reports suggest that microglia are of myeloid origin (Chan et al., 2007). They appear 
for the first time at an early embryonic state in the neuroepithelium and populate the brain 
from the blood in a second perinatal phase. Under pathological conditions or infections, 
microglia migrate to the affected tissue. On site, they change their phenotype to a pro-
inflammatory cell type, release cytotoxic molecules such as reactive oxygen species to fight 
against microbes or clear tissue debris after sterile injury. Microglia also phagocyte 
oncogenically transformed brain cells and are able to activate additional immune cells. Pro-
inflammatory microglial cells are also involved in the progression of neurodegenerative 
diseases.  
Research on microglia is mainly performed on primary cells. However, only a limited 
amount of murine or human microglial cells can be obtained from the brain tissue, thus 
complicating investigations of drug screenings or new cell therapy approaches that are 
requiring a high number of cells. For this reason, stem cell-derived microglia represent a 
useful tool for further studies to elucidate the role of microglia in diseases and therapeutical 
approaches. Data from others and our laboratory show that microglial precursor cell lines 
can be obtained from mouse embryonic stem cells or human induced pluripotent stem cells 
via a neural differentiation protocol. Human microglial cell lines open new alternatives for 
drug screening, combating cancer and regenerative approaches for neurological diseases. 
2. Microglia in neuroinflammation and neurodegeneration 
The CNS contains two major cell types: neurons and glial cells. Neurons build a network 
throughout the nervous system and forward information through electrical conduction. 
Glial cells are only indirectly involved in the conduction process, but play an essential 
supportive role to neurons. Glial cells of the CNS can be subdivided into two main classes: 
macroglia consisting of astrocytes and oligodendrocytes and microglia. Microglia are the 
only immune competent cells in the intact CNS. They were defined by Ramon Y Cajal in 
1913 as a third group of cells in the CNS and termed mesoglia (Rezaie and Male, 2002). 
Microglial cells were further characterized by Rio del Hortega using silver carbonate 
staining (del Rio-Hortega, 1933). He defined the term microglia and proposed that they can 
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change their morphology dependent on their activation state. Microglial distribution varies 
by brain region, but they predominate in the grey matter with highest concentrations in the 
hippocampus, the substantia nigra, the olfactory telencephalon and the basal ganglia (Block 
et al., 2007). In the healthy CNS the so called ‘resting’ microglia display a ramified 
morphology. However, microglial cells are not resting at all, but continuously survey their 
microenvironment with their processes. Time-laps imaging using in vivo two-photon 
microscopy revealed that the somata of microglial cells remain stably localized whereas the 
processes are remarkable motile (Nimmerjahn et al., 2005). The microglial processes show 
continuous cycles of withdrawal and new formation, thereby scanning the whole brain 
parenchyma every few hours. Upon immunological stimuli or in response to brain injuries 
microglia become activated and migrate towards the stimuli. At the lesion site they change 
their phenotype from a ramified to an amoeboid morphology, clear debris and apoptotic 
cells and promote tissue repair. It was reported that microglia increase neuronal survival 
through the release of trophic and anti-inflammatory factors (Block et al., 2007; Streit, 2002). 
In their activated state microglia up-regulate several surface molecules such as CD14, major 
histocompatibility complex (MHC) molecules, complement receptors and chemokine 
receptors (Rock et al., 2004). Furthermore, pro-inflammatory activated microglia release a 
wide range of soluble factors like superoxide, nitric oxide and tumor necrosis factor-┙ 
(TNF┙), which have neurotoxic effects on neurons. It seems that microglia have both, 
neuroprotective and neurodestructive functions. In contrast to acute CNS injuries, chronic 
diseases are characterized by slow progressive neurodegeneration that takes years to 
develop (Streit, 2002). There is strong evidence that microglial cells are involved in a wide 
range of neurodegenerative diseases (Block and Hong, 2005) like Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington’s disease 
(HD). Actually, AD was one of the first neurodegenerative diseases associated with 
neurotoxic microglia (Block and Hong, 2005). AD is a neurodegenerative disorder leading to 
cognitive, memory and behavioral impairments. The pathological hallmark of AD consists 
of cortical atrophy with accumulation of extracellular deposits of amyloid ┚ (A┚) in senile 
plaques and intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau protein 
in the cerebral cortex (De Strooper and Annaert, 2000). Senile A┚ plaques recruit and 
activate microglia, which in turn produce pro-inflammatory factors that act neurotoxic on 
neurons. Damaged neurons activate microglia independent of the mode of damage. Finally, 
this leads to neurotoxin producing microglia resulting in a perpetuating toxicity.  
3. Origin and sources of microglia 
During embryonic development gastrulation conduces to the creation of the three germ 
layers: ectoderm, mesoderm and endoderm (Arnold and Robertson, 2009). The ectoderm 
gives raise to the peripheral and central nervous system as well as to the epidermis 
structures. The mesoderm which is located between the endoderm and ectoderm develops 
into blood, muscles, bone, cartilage, notochord and the connective tissue. Organs associated 
with the digestive system such as pancreas, liver and the epithelium of the digestive and 
respiratory system are of endodermal origin. 
The origin of microglia is still under debate due to the lack of a specific microglial marker. 
There are different hypotheses about the origin of microglia. In previous times some 
scientists held the view that microglia are of neuroectodermal origin and are derived from 
either the ventricular zone of the lateral ventricle or glioblasts (Kitamura et al., 1984; 
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Paterson et al., 1973). Kitamura and colleagues (Kitamura et al., 1984) used 3H-thymidine 
autoradiographic analysis to investigate the genesis of microglia within the mouse 
hippocampus. They concluded that resting microglia originate from glioblasts, direct 
derivatives of matrix cells, that are of neuroectodermal origin. Interestingly, the possibility 
that microglia might be derived from the neuroectoderm via a mesenchymal stem cell type 
was supported by a recent publication (Takashima et al., 2007). Embryonic stem cells were 
cultivated and differentiated under two different conditions, one gave rise to mesodermal 
cells and the other one generated cells from the neuroectodermal lineage. Takashima and 
colleagues could show that mesenchymal stem cells (MSC) do not develop from 
mesodermal cells but from cells positive for Sox1, a molecular marker specifically expressed 
on neuroepithelial cells. They concluded that this way is representing the earliest 
recruitment of MSCs, whereas the origin of the later waves remains unsolved.  
However, in 2002 it was shown that microglia express the transcription factor PU.1, which is 
myeloid specific. Therefore, it was suggested that prenatal microglia are derived from 
mesenchymal cells from the myeloid lineage (Rezaie and Male, 2002). Various monoclonal 
antibodies that are used to identify monocytes and macrophages like CD11b, CD45, CD68 
and MHC class II also label microglia which supports the notion that microglia are derived 
from blood monocytes or another monocyte-related myeloid cell type. This view was further 
supported by the discovery that the first appearance of microglial cells coincide with the 
vascularization of the brain. It was suggested that circulating monocytes enter the nervous 
system and transform to microglia (Imamoto and Leblond, 1978; Ling, 1979) before the 
formation of the blood-brain-barrier has been completed (Perry et al., 1985). Infiltration of 
monocytes could be confirmed by carbon-labelling (Ling et al., 1980) and histochemical 
studies using marker enzymes for monocytes (Ferrer and Sarmiento, 1980; Ling et al., 1982).  
Andjelkovic and colleagues labelled microglia in the developing and adult human brain 
using lectin-histochemistry (Andjelkovic et al., 1998). Lectin positive cells can be subdivided 
into two groups which both exist in the adult brain, but show different distribution and time 
schedule of morphological changes. Their results support the consideration that there could 
be different origins of microglia.  
Two questions remain to be answered: when do the first microglia appear and what is their 
origin. It has been established that microglial progenitors populate the nervous system 
during embryonic and fetal development (Rezaie and Male, 1999). Some authors have 
suggested the yolk sac as the tissue of origin for all tissue macrophages during embryonic 
development (Alliot et al., 1999; Kaur et al., 2001). Alliot and colleagues (1999) reported that 
cells with properties of microglial precursors can be first detected at embryonic day E8 in 
mice and that the majority of these progenitors originate from the yolk sac.  
Nowadays, it is suggested that microglia populate the brain in two waves. The first one 
takes place in the neuroepithelium during embryonic development around E8-9  in rodents 
with unknown origin (Alliot et al., 1999). The second wave occurs in the brain during fetal 
development at E17-18. These cells are derived from a pool of circulating myeloid precursor 
cells of mesodermal origin (Chan et al., 2007).  
In the adulthood, it is widely accepted that microglia invading the diseased CNS are derived 
from circulating monocytes originating in the bone marrow (Perry et al., 1985; Rezaie and 
Male, 2002). It was described that in bone marrow chimeric mice circulating monocytes are 
recruited to the lesion site of the brain and differentiate into microglia (Mildner et al., 2007). 
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However, it seems that the inappropriate stimulus of irradiation is required for the 
recruitment (Mildner et al., 2007). 
Microglial function is often studied on primary microglial cells, which are isolated and 
enriched from mixed glial cultures derived from the brains of postnatal mice or rats. But the 
cell number obtained by a shaking procedure from mixed glial culture flasks is rather low 
(Giulian and Baker, 1986). Optionally, a pure population of microglial cells can be obtained 
using a combination of density gradients and flow cytometric sorting (Ford et al., 1995). This 
methodology is applied to isolate both mouse and human microglia. However, the obtained 
number of primary microglia is very limited in rodents and humans. This aspect 
complicates classical biochemistry studies, systematic screening tests or cell therapy 
approaches. Therefore, the BV2 cell line which is originated from primary mouse microglia 
by oncogenetic transformation (Blasi et al., 1990; Bocchini et al., 1992) is used as a substitute 
for primary microglia. Murine cultured microglia are immortalized via injection with v-
raf/v-myc recombinant retroviruses. The obtained BV2 cells show properties like 
macrophages in terms of antigen profile and phagocytic capacity. However, due to the 
transformation process these cells show an altered cytokine profile and changes in their 
migratory capacity (Horvath et al., 2008; Napoli et al., 2009). Later on, Nagai and colleagues 
established an immortalized cell line of human microglia termed HMO6 (Nagai et al., 2005; 
Nagai et al., 2001). This cell line is developed from human embryonic telencephalon tissue 
by retroviral transformation with v-myc. Certainly, these cells can not be used in 
therapeutical approaches due to the usage of retroviruses for transformation. Therefore, 
microglia derived from embryonic stem (ES) cells might provide a new tool to study 
microglial function and to apply them for cellular therapies. 
4. Embryonic and induced pluripotent stem cell-derived microglia 
During the last decades a major breakthrough was the development of mouse pluripotent 
embryonic stem cell lines (Evans and Kaufman, 1981). These cells are isolated from the inner 
cell mass of embryos and can be cultivated in vitro on a feeder layer of mouse embryonic 
fibroblasts (MEF) in the presence of the leukemia inhibitory factor (LIF). In addition to the 
MEF, which are supposed to secrete crucial factors to promote self-renewal, cultivated 
murine ES (mES) cell lines also require the presence of LIF to maintain their undifferentiated 
stage (Smith et al., 1988; Williams et al., 1988). In culture, mES cell lines show an almost 
unlimited proliferation capacity and maintain nearly a normal and stable karyotype (Smith, 
2001). During cultivation ES cell lines do not loose their pluripotency and are able to 
generate all cell types of an embryo (Wobus and Boheler, 2005).  
Due to their crucial role in neurodegenerative diseases microglia could be used as a cellular 
vehicle for gene or regenerative therapies in the CNS (Neumann, 2006). The CNS is 
delimited from the circulating blood by the blood-brain-barrier which controls the entry of 
substances and molecules. Theoretically, only 2 % of small molecules are able to enter the 
CNS, whereas large molecules are unable to pass the blood-brain-barrier. Therefore, only a 
limited number of drugs can be introduced in CNS diseases. Microglial cells are a migratory 
cell type that is able to pass the blood-brain-barrier and could therefore be used as a vehicle 
to introduce therapeutical proteins into the CNS to the affected tissue. 
As already discussed, the obtained number of primary microglia is very limited in rodents 
and humans using the before mentioned protocols. Contrary to these methods, the 
generation of microglia derived from pluripotent stem cells constitute a source of unlimited 
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numbers of microglia which can be used for biochemical studies, systemic screening tests 
and cell therapy approaches. Recently, a protocol for the generation of microglia derived 
from mES cells was developed (Beutner et al., 2010; Napoli et al., 2009). This effort was 
initiated by a work from Tsuchiya and colleagues who succeeded in the differentiation of 
microglial-like cells derived from mES cells (Tsuchiya et al., 2005). During their neuronal 
differentiation based on a protocol for the generation of dopaminergic neurons (Lee et al., 
2000) they found a population positive for Iba1 and CD45. Using a density gradient, these 
cells with morphological characteristics of primary microglia could be isolated. However, 
these isolated cells were not described to survive and proliferate. Thus, we generated a 
protocol to obtain microglial precursors from mES cells (Beutner et al., 2010; Napoli et al., 
2009). These ES cell derived microglial precursors (ESdM) are stable proliferating in culture 
and have substantially most characteristics of primary microglia. The differentiation of mES 
cells to microglial precursors requires a five step protocol (Beutner et al., 2010). ES cells are 
cultivated on an irradiated MEF layer in defined medium in the presence of LIF. To induce 
spontaneous differentiation, ES cell clusters are detached and cultured on non-adherent 
culture dishes without LIF. So called embryoid bodies (EBs) are generated and plated on 
gelatine-coated cell culture dishes in ITS-medium supplemented with fibronectin. Under 
these conditions cells start to proliferate and different cell types develop. Most of these cells 
can be immunostained against the intermediate filament protein nestin which is mostly 
expressed by neuronal precursors. After 6 days in this selection stage medium is changed to 
N2-medium to expand cells in the presence of FGF2 and laminin for 6 more days. 
Withdrawal of FGF2 induces differentiation of neurons, astrocytes and oligodendrocytes 
(Beutner et al., 2010). Within this mixed cell culture cells with microglial morphology can be 
detected around three weeks after removal of FGF2. The proliferation of these cells can be 
enhanced through addition of granulocyte macrophage colony stimulating factor (GM-CSF). 
Microglial precursors are manually isolated and cultivated in N2-medium. They attach to 
the cell culture dish and typically follow an exponential growth rate. Expression of the 
marker Iba1 and CD68 indicate that the isolated cells are microglial precursor cells derived 
from mouse embryonic stem cells. Comparable to primary microglia ESdM show high 
expression of CD11b and CD45 (Beutner et al., 2010). Analysis of ┙4 integrin and ┚1 integrin 
show high expression levels of these two integrins by ESdM and primary microglia. In 
contrast, the expression of CD34 and cKit which are both expressed on certain stem cell 
populations can not be confirmed indicating that ESdM cell lines lost their stem cell 
properties. Besides, ESdM show expression of B7.2, a costimulatory ligand that is expressed 
on antigen-presenting cells and that together with its receptor is responsible for T and B cell 
activation. In addition, a weak expression of major histocompatibility complex (MHC) class 
II which is also expressed on antigen-presenting cells can be confirmed. Up to passage 20 no 
relevant changes of the surface marker profile can be observed. However, from passage 25 
onwards ESdM lines show a decreased expression of the analyzed markers indicating that 
the phenotype is not stable over very long proliferation periods. 
A typical hallmark of microglia is the inducibility of pro-inflammatory cytokines and reactive 
oxygen species after stimulation. ESdM cell lines and primary microglia stimulated with 
lipopolysaccharide (LPS) show an upregulation of inducible nitric oxide synthase (iNOS) and 
interleukin 1┚ (IL-1┚) transcript levels (Beutner et al., 2010; Napoli et al., 2009). Interferon-┛ 
(IFN┛) stimulation results in an increase in iNOS transcripts in ESdM comparable to primary 
microglia whereas IL-1┚ gene transcription is almost not affected in both cell types. 
Furthermore, a chemokine assay determines that ESdM migrate towards the chemokine 
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CX3CL1 in a dose-dependent manner (Beutner et al., 2010). Comparable to primary microglia, 
migration is significantly increased following a CX3CL1 gradient. The phagocytic capacity is 
an important aspect of microglia. After LPS stimulation ESdM show an increase in 
phagocytosis of microsphere beads in comparison to unstimulated cells (Beutner et al., 2010).  
In summary, ESdM show most characteristics of primary microglia and therefore can be 
seen as a new promising tool to study microglial function in vitro and in vivo. 
In 2006, Takahashi and Yamanaka identified 24 potential candidate genes that were thought 
to be involved in maintaining pluripotency and self renewal of ES cells (Takahashi and 
Yamanaka, 2006). They showed that reprogramming of mouse embryonic fibroblasts to an 
embryonic-like state is possible after retroviral transduction with the four factors Oct4, Sox2, 
Klf4 and c-Myc. These so called induced pluripotent stem (iPS) cells showed similarities to 
ES cells in terms of morphology, proliferation and expression of pluripotency markers. 
Furthermore, iPS cells are able to differentiate into all three germ layers and therefore can be 
used to generate every cell type of the body. Some month later different groups succeeded 
in the generation of iPS cells from human adult fibroblasts (Takahashi et al., 2007b; Yu et al., 
2007). Fibroblasts are obtained from human skin tissue biopsies and cultured under defined 
conditions. For reprogramming, human fibroblasts are retrovirally co-transduced with Oct4, 
Sox2, c-Myc and Klf4 genes. The obtained iPS cells are cultured according to protocols 
established for human embryonic stem cells. The analysis of iPS cells shows that they display a 
normal morphology, a normal karyotype and the expression of several pluripotency markers 
like Oct4, SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81. Furthermore, multilineage differentiation of 
iPS cells is confirmed by embryoid body and teratoma formation. However, the generation of 
iPS cells using retroviruses includes the integration of genetic material and thereby the 
potential risk of genetic modifications of the target cells. To overcome this issue modified 
methods were developed to generate iPS cells (Yamanaka, 2009). Recently, it was shown that 
proteins conjugated with a short peptide mediating protein transduction can be directly 
delivered into the target cell. Using recombinant cell-penetrating reprogramming proteins, iPS 
cells are obtained from mouse fibroblasts (Zhou et al., 2009). 
In a next step, human iPS cells are used for differentiation into microglial precursors 
(unpublished, pending European patent EP2010_055731). A differentiation protocol is applied 
with nearly the same five steps described for the generation of ESdM. Human iPS cells are 
cultured on a layer of irradiated MEF in the presence of FGF2. After some days in culture, iPS 
colonies can be detached and cultivated on non-adherent dishes without any growth factors to 
induce spontaneous differentiation. The resulting EBs are allowed to attach to the culture dish 
and grow out in defined medium supplemented with FGF2 and fibronectin. For expansion of 
the cells medium is changed to N2-medium in the presence of FGF2 and laminin. Withdrawal 
of the growth factor after some days induces the differentiation of microglial precursors 
identified by morphology. Microglial identity is confirmed using immunocytochemical 
analysis with antibodies against the microglial marker Iba1 and CD68. The iPS-derived 
microglial precursor (iPSdM) cells can be isolated and cultivated. Because disease-specific iPS 
cells (Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009) can be generated, this method 
might represent a new tool for regenerative medicine for study and treatment of disease 
models.  
5. Target pathway identification and drug screening 
Drug discovery processes are costly in terms of time and expenses. High throughput rate 
screening technologies allow rapid testing of compounds, but might lack physiological 
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conditions. Classically two distinct sources of human cell types, primary or immortalized 
cell lines, are available for drug screening technologies (Ebert and Svendsen, 2010). Primary 
cell lines are fully differentiated cell types with close approximation of native function, but 
often are inaccessible, require fresh preparation and have questionable reproducibility. In 
principal, primary microglial cell lines are not available due to the inaccessibility of the 
human brain tissue and difficulty to maintain the cells in culture. 
In contrast, immortalized cell lines have low costs for maintenance and are homogenous cell 
populations, but lack important aspects of native cells such as certain metabolic or 
migratory functions. Furthermore, many cell types are not available as immortalized cell 
lines. In literature, a human immortalized microglia cell line was described (Nagai et al., 
2005; Nagai et al., 2001). This cell line (HMO6) is developed from human embryonic 
telencephalon tissue by retroviral transformation with v-myc and is reported to possess 
most immunological and functional characteristics of primary microglia. However, in 
comparison to primary microglia, HMO6 cells display an altered cytokine profile (Nagai et 
al., 2001). Therefore, they probably do not fully reflect the properties of primary microglia. 
Now, a new technology to obtain human microglial cells becomes available for drug 
screening technologies. As described above for microglia, embryonic stem cells or induced 
pluripotent stem cells can be differentiated into stably proliferating cell types. Most adult 
tissue cell types including microglia can be obtained at high quantities using this 
technology. The tissue cell types differentiated from stem cells show functional properties 
very close to the native cell types. Most interestingly, cell lines can be generated from 
diseased patients, too. However, reproducible methods to obtain fully differentiated cells 
and to achieve purified populations are still under development. As described above, 
microglial lines now can be generated from human induced pluripotent stem cells, which 
reflect very much the native function of primary microglia. The microglial lines can then be 
used for screening technologies. 
One possible use of human microglial cell lines could be screening tests to evaluate the effect 
of new possible drugs or substances that might act toxic. Nanoparticles which are sized 
between 1 and 100 nm are basically of interest in pharmacy and medicine as the number of 
products containing synthesized nanoparticles steadily increases. Orally absorbed 
nanoparticles via drugs or food can pass the blood system via the gut. It was reported that 
silica crystals can activate immune cells, are phagocytosed and transported into the 
lysosome (Hornung et al., 2008). Given that these nanoparticles can not be digested, 
lysosomal swelling and damage might be induced in phagocytes including microglia. In 
addition, lysosomal damage activates the inflammasome and the release of the pro-
inflammatory cytokine IL-1┚. It is expected that the size, structure and type of nanoparticles 
might influence this lysosomal toxicity. Interestingly, aggregated amyloid ┚ (A┚) which is 
involved in the pathology of AD and exhibit a size of 10 – 200 nm can activate microglia in a 
similar way (Halle et al., 2008). Halle and colleagues demonstrated that microglia 
phagocytose fibrillar A┚ and transport it into the lysosome, where it induces swelling and 
damage of this organelle. The inflammasome of microglia is activated which leads to the 
release of inflammatory mediators like IL-1┚. Furthermore, diesel exhaust particles (DEP) 
mediate the neurotoxicity on dopaminergic neurons caused by microglia, possibly by a 
similar mechanism (Block et al., 2004). Diesel exhaust particles uptake leads to the activation 
of microglia and their production of reactive oxygen species and nitric oxide, which induces 
toxicity of dopaminergic neurons. In summary, nanoparticles and other small particles 
principally have the risk to activate microglia leading to the release of pro-inflammatory 
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cytokines and radicals which can promote the pathology of neurodegenerative diseases. 
Thus, microglial lines could help to evaluate the possible brain toxicity of very small 
particles. 
Another possibility to use human microglial cell lines for screening is the development of 
novel drugs for neurodegenerative diseases. Activated microglia are reported to be involved 
in the pathology of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). 
Approximately, 10 – 20 % of patients with familiar ALS show a mutation in the superoxide 
dismutase-1 (SOD1) gene whose product is involved in the conversion of free superoxide 
radicals. In an animal model of ALS it was demonstrated that microglia with mutant SOD1 
drive the disease onset and progression in particular via the release of pro-inflammatory 
molecules and radicals (Boillee and Cleveland, 2008). Mutant SOD1 stimulates the NADPH 
oxidase resulting in an overproduction of reactive oxygen species (ROS). Therefore, it is 
proposed that ROS produced by microglia mediate the pathogenesis of familiar ALS 
associated with a mutation of SOD1.  
Human iPS-derived microglia cell lines would provide a new possibility to investigate the 
effect of different SOD1 mutations on the toxicity of microglia. Therefore, iPS-derived 
microglia could be transduced with mutant SOD1 or obtained from patients with a SOD1 
mutation and analyzed for abnormal radical and pro-inflammatory cytokine production. 
Furthermore, co-culture of those genetically modified or mutated microglia and motor 
neurons could give more insight in the pathology of the disease. 
Since iPS cells can be generated from diseased patients (Dimos et al., 2008; Ebert et al., 2009; 
Park et al., 2008) they represent a new tool for disease modelling screens of several 
neurodegenerative diseases. Ideally, iPS cells are expanded and differentiated in the disease 
relevant cell type such as microglia. The differentiated cell type would allow drug screening 
tests and investigations of genes differently regulated or mutated in this cell type. 
In summary, iPS-derived microglia represent human conditions better than other cell lines, 
thus allowing drug screening and identification of pathways affected in neurodegenerative 
diseases. 
6. Combating cancer 
The most common and aggressive type of primary brain tumors in humans is the glioma, 
which most probably arises from glial cells or their progenitor cells. As primary tumors, 
gliomas occur rather rarely with an estimated prevalence of 15 cases for 100 000 people 
(American Cancer Society, 2006). These anaplastic and malignant tumors result in a median 
of survival after diagnosis from 2 to 8 months, depending on the age of the patient (Curran 
et al., 1993; Scott and Mickle, 1987). One of the major problems in combating tumors is their 
ability to override the immune system. They are known to express a variety of 
immunosuppressive molecules like interleukin-10 (IL-10), prostaglandin E2 or transforming 
growth factor-┚ (TGF┚) (Wiendl et al., 2002; Wischhusen et al., 2002; Wrann et al., 1987). The 
secretion of these molecules leads to a local immunosuppression as well as to a systemic 
immunodeficiency (Platten et al., 2001). 
The main treatment of glioma is surgical therapy, whereas the extent of the tumor resection 
closely correlates with the survival time of the patient (Jeremic et al., 2003; Keles and Berger, 
2004; Soffietti et al., 1989). Nevertheless, brain surgery is not capable of removing all tumor 
cells. Thus, infiltrating tumor cells still reside in the healthy brain tissue and cause 
reformation of gliomas. Radiotherapy is another standard therapy for treatment of glioma. 
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But, in respect to long term survival, no effect of radiation alone is found in case of grade II 
gliomas (Karim et al., 2002). 
In addition to these treatments, chemotherapy is commonly used. Chemotherapy aims at the 
impairment of cell division, which mostly affects fast-dividing cells including tumor cells. 
One of the biggest disadvantages of this therapy is the side effect caused by the effects on 
healthy dividing cells, which leads to hair loss and damage of the intestinal epithelium 
(Krauseneck and Muller, 1994). 
Still, those therapies do not result in a satisfactory therapy of gliomas and there is need for 
new therapeutical approaches. 
Experimental therapies are aiming at several mechanisms in tumor progression. On a 
molecular level, therapies aim at the cancer specific signal cascades and molecules to 
influence proliferation, invasion and angiogenesis (Adjei and Hidalgo, 2005; Krause et al., 
2005). One of the most promising targets is TGF┚. Encouraging data of longer survival rates 
and slower tumor growth was obtained using a TGF┚ antisense oligonucleotide for the 
treatment of human glioblastoma (Schlingensiepen et al., 2006). These findings were 
endowed by animal experiments and in vitro data (Jachimczak et al., 1996). The platelet 
derived growth factor receptor (PDGFR) is another possible candidate in molecular 
approaches of combating cancer. Upon inhibition of this receptor with imatinib, the tumor 
growth rate decreases and even complete remission can be observed in some patients 
(Dresemann, 2005). 
Another approach in this field is the active specific immunotherapy which includes the in 
vivo induction of tumor-specific cytotoxic T lymphocytes. Upon induction, those cells are 
likely to be able to trigger apoptosis of tumor cells (Kagi et al., 1994).  
During the recent years, focus has been cast on gene-based therapy in regard to malign 
gliomas. Mostly, adenoviral and retroviral vectors are used to deliver genes with therapeutic 
effects into the glioma site. The most promising candidates are oncolytic gene therapy and 
gene transfer of p53 or interferon-┚ (IFN┚) (Lang et al., 2003; Mineta et al., 1995; Yoshida and 
Tanaka, 2004). It was demonstrated that bone marrow derived cells express thymidine 
kinase of herpes simplex virus have a therapeutic effect on gliomas through bystander-
mediated glioma cell killing after gancyclovir application (Miletic et al., 2007). 
Microglia are known to be attracted by and to infiltrate the glioma site (Umemura et al., 
2008). However, their phagocytic ability, antigen presentation and secretion of pro-
inflammatory cytokines is suppressed by the tumor cells (Hanisch and Kettenmann, 2007; 
Komohara et al., 2008; Yang et al., 2010). These tumor-infiltrating microglial cells obtain an 
immunosuppressive phenotype and promote TGF┚ production via an autocrine loop 
(Umemura et al., 2008). In addition to the immunosuppressive cytokine milieu provided by 
the glioma cells, this leads to T cell tolerance and inactivation of tumor targeted immune 
responses (Carpentier and Meng, 2006). Nevertheless, microglia are potent immune effector 
cells and are able to mediate the innate and boost adaptive immune responses. It is known 
that the classical activated microglial cell, in contrast to the alternatively activated microglia 
with an immunosuppressive phenotype, could phagocytose glioma cells and furthermore 
create a pro-inflammatory milieu (Mantovani et al., 2004). Additionally, chemokines from 
microglia are known to attract cytotoxic cells such as natural killer cells (Carter et al., 2007; 
Hughes et al., 2002; Napoli and Neumann, 2009), they yield a high potential for 
immunostimulatory therapy approach. Clearly, microglia are situated ideally within the 
CNS to confront migrating and resident tumor cells. Another feature of microglia is their 
ability to migrate from the blood stream into the CNS, which makes them an interesting 
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vehicle for therapeutic gene transfer into mature CNS tissue and the tumor residuum 
(Flugel et al., 2001). 
Thus, the resolution of the immunosuppressive milieu by triggering a cytotoxic phenotype 
of microglia in the glioma site in combination with recruitment of cytotoxic leukocytes 
yields a promising approach. Especially microglial cells derived from embryonic stem cells 
appear suitable for therapy approaches, as they have unlimited proliferative potential and 
differentiated cells bear the potential to stimulate cytotoxicity towards glioma cells. Thus, 
iPSdM might therefore be a suitable and powerful tool for immune system-based or gene-
transfer-based cell therapy of human glioma. 
7. Regenerative approaches 
Microglial cells are the immune effector cells which mediate immune responses in the CNS. 
They are known to play crucial roles in several neurodegenerative diseases such as multiple 
sclerosis (MS), AD or PD. Thus, they are an interesting target for regenerative therapies. 
In MS, the immune system reacts with a destructive immune response against antigens of 
the CNS like myelin basic protein (MBP) or myelin oligodendrocyte glycoprotein (MOG), 
which leads to demyelination and axonal injury (Mattson and Taub, 2004). During disease 
course, scar-like plaques appear around the damaged axons, called lesions (Chari, 2007). 
Additional to the process of demyelination, inflammation is a hallmark of MS. This 
inflammation is mainly mediated by activated T cells, which invade the brain via the blood-
brain-barrier and attack the myelin sheath of axons (Compston and Coles, 2002; 
Wucherpfennig and Strominger, 1995). This subsequently leads to stimulation of other 
immune cells like microglia and macrophages, which then secrete inflammatory cytokines 
(Cannella and Raine, 1995). This in turn leads to further recruitment of T cells, B cells and 
macrophages to the inflammation site (Steinman et al., 2002). 
Until now, there is no known cure for MS, though some improvement in prevention of attacks 
and disability could be achieved through administration of immunosuppressants like 
interferons (Comi, 2009). Nevertheless, there is still need for other therapeutical approaches, 
especially in regard to neuroprotection and regeneration. Stem cell research has lead to new 
approaches in addressing neuroinflammatory disorders. Several cell types have been used for 
experimental therapies. Neural stem cells have been reported to migrate to inflammation sites 
in the CNS and to contribute to functional recovery and tissue repair (Pluchino et al., 2003). A 
similar beneficial effect was shown using bone marrow cells in experimental autoimmune 
encephalomyelitis (EAE), a mouse model for MS (Zappia et al., 2005). 
It has been shown that microglia are able to pass the blood-brain-barrier and migrate into 
the brain under pathological conditions (Imai et al., 1997). In our group, we could show that 
ESdM like other bone marrow derived myeloid precursors migrate to lesion sites in EAE 
afflicted mice. Bone marrow myeloid precursors as putative progenitors of microglia have a 
beneficial impact after transduction with the microglial receptor triggering receptor 
expressed on myeloid cells-2 (TREM2) on the clinical course of EAE, on demyelination and 
axonal damage (Takahashi et al., 2007a). Furthermore, an anti-inflammatory milieu is 
established in the lesion sites due to the treatment (Takahashi et al., 2007a). Similar effects 
might be expected after transplantation of microglial precursor cells that are derived from 
ES cells and constitutively expressing TREM2. 
As iPS-derived microglia principally can be generated from human iPS cells without 
oncogenic transformation and in high numbers, they might be a suitable and save vehicle 
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for neurotrophic factors to be released at inflammatory lesions in MS. In regard to AD, 
microglia can be seen as a possible therapeutic target, too. The pathological hallmarks of AD 
are cortical atrophy with accumulation of extracellular deposits of amyloid ┚ (A┚) in senile 
plaques and intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau in the 
cerebral cortex (De Strooper and Annaert, 2000). It is known that A┚ serves as a microglial 
activator and leads to production of various inflammatory mediators (Benveniste et al., 
2001). On the other hand, a neuroprotective role of microglia was found in AD. Activated 
microglia migrate to A┚ plaques, where they release proteolytic enzymes like 
metalloproteinases that degrade A┚ (Qiu et al., 1997). Although it is unclear why microglia 
fail to completely clear the A┚ plaques by phagocytosis, at least they appear to restrict 
plaque growth (Bolmont et al., 2008). Nevertheless, it was reported that administration of 
exogenously applied microglia in a rat animal model of AD increases A┚ clearance (Takata 
et al., 2007). It has been shown by several groups that bone marrow-derived cells are capable 
of becoming brain macrophages, which then might play a major role in A┚ clearance (Malm 
et al., 2005; Simard and Rivest, 2004). Therefore, microglial cells may be a suitable tool for 
clinical application, if they are able to overcome the blood-brain-barrier. This problem could 
be addressed by irradiation (Ajami et al., 2007) or by intra-arterial injection (Imai et al., 
1997), which both facilitates the entry of microglia into the brain. Otherwise, it would be 
possible to directly apply the iPS-derived microglia into the CNS by local transplantation. 
Thus, iPS-derived microglia might broaden the therapeutical approaches in AD, as they 
might be able to clear A┚ plaques and attenuate disease course. 
8. Conclusion 
Microglia are involved in a variety of neurodegenerative diseases. They are a promising 
target for new therapies. Their role as immune effector cells in the CNS might yield 
interesting perspectives for locally modulating the cytokine milieu or phagocytic properties 
to influence the disease course in a beneficial way. Glioma is the most common brain tumor 
which is not curable so far. Microglia were demonstrated to phagocytose glioma cells and 
attract cytotoxic cells to the glioma site. Therefore, they display a high potential for usage in 
therapy. In addition, microglia were shown to migrate from the blood stream into the CNS 
which makes them a suitable cellular vehicle for therapeutic gene transfer. Microglia 
overexpressing neurotrophic factors could contribute to the regeneration of lesioned brain 
tissue. Therefore, the generation of microglia from embryonic stem cells and iPS cells 
provides a new technology for combating cancer and for usage in regenerative medicine. 
Since iPS-derived microglia resemble human primary cells they can be further used in drug 
screening tests. It has been shown that very small sized particles such as nanoparticles could 
principally activate microglia. This leads to the production of pro-inflammatory cytokines 
and radicals by microglia which in turns promotes the pathology of neurodegenerative 
diseases. Therefore, iPS-derived microglia provide a new tool to evaluate the possible 
toxicity of very small-sized particles to the CNS. 
9. Acknowledgements 
The Neural Regeneration Group at the University of Bonn Life & Brain Center is supported 
by the Hertie Foundation, the Walter und Ilse Rose Foundation, the Deutsche 
Forschungsgemeinschaft (FOR1336, KFO177, SFB704) and the EU (LSHM-CT-2005-018637). 
www.intechopen.com
 Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-Based Regenerative Medicine 
 
182 
We thank J. Schumacher and R. Hass for excellent technical support of cultures and 
molecular biology. 
10. Conflict of interest 
K.R. and H.N. have interest in royalty rights on a pending European patent EP2010_055731, 
Method for obtaining human microglial precursor cells from pluripotent stem cells’. H.N 
has interest in royalty rights on a pending European patent EP2010_055725 ‚Microglial 
precursor cells for the treatment of malignant neoplasms of the central nervous system’. 
11. References 
Adjei AA, Hidalgo M. Treating cancer by blocking cell signals. J Clin Oncol, 2005; 23: 5279-
80. 
Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS 
microglia maintenance and function throughout adult life. Nat Neurosci, 2007; 10: 
1538-43. 
Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, 
and which proliferate in the brain. Brain Res Dev Brain Res, 1999; 117: 145-52. 
Andjelkovic AV, Nikolic B, Pachter JS, Zecevic N. Macrophages/microglial cells in human 
central nervous system during development: an immunohistochemical study. Brain 
Res, 1998; 814: 13-25. 
Arnold SJ, Robertson EJ. Making a commitment: cell lineage allocation and axis patterning 
in the early mouse embryo. Nat Rev Mol Cell Biol, 2009; 10: 91-103. 
Benveniste EN, Nguyen VT, O'Keefe GM. Immunological aspects of microglia: relevance to 
Alzheimer's disease. Neurochem Int, 2001; 39: 381-91. 
Beutner C, Roy K, Linnartz B, Napoli I, Neumann H. Generation of microglial cells from 
mouse embryonic stem cells. Nat Protoc, 2010; 5: 1481-94. 
Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial 
cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol, 1990; 27: 229-37. 
Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple 
triggers with a common mechanism. Prog Neurobiol, 2005; 76: 77-98. 
Block ML, Wu X, Pei Z, Li G, Wang T, Qin L, Wilson B, Yang J, Hong JS, Veronesi B. 
Nanometer size diesel exhaust particles are selectively toxic to dopaminergic 
neurons: the role of microglia, phagocytosis, and NADPH oxidase. FASEB J, 2004; 
18: 1618-20. 
Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular 
mechanisms. Nat Rev Neurosci, 2007; 8: 57-69. 
Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H. An immortalized cell line 
expresses properties of activated microglial cells. J Neurosci Res, 1992; 31: 616-21. 
Boillee S, Cleveland DW. Revisiting oxidative damage in ALS: microglia, Nox, and mutant 
SOD1. J Clin Invest, 2008; 118: 474-8. 
Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, 
Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in 
plaque maintenance. J Neurosci, 2008; 28: 4283-92. 
Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis 
lesions. Ann Neurol, 1995; 37: 424-35. 
www.intechopen.com
Perspectives of Stem Cell-Derived Microglia for Medicine   
 
183 
Carpentier AF, Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin 
Oncol, 2006; 18: 631-6. 
Carter SL, Muller M, Manders PM, Campbell IL. Induction of the genes for Cxcl9 and Cxcl10 
is dependent on IFN-gamma but shows differential cellular expression in 
experimental autoimmune encephalomyelitis and by astrocytes and microglia in 
vitro. Glia, 2007; 55: 1728-39. 
Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. Brain 
Res Rev, 2007; 53: 344-54. 
Chari DM. Remyelination in multiple sclerosis. Int Rev Neurobiol, 2007; 79: 589-620. 
Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon 
beta. Clin Ther, 2009; 31: 1142-57. 
Compston A, Coles A. Multiple sclerosis. Lancet, 2002; 359: 1221-31. 
Curran WJ, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, 
Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of 
prognostic factors in three Radiation Therapy Oncology Group malignant glioma 
trials. J Natl Cancer Inst, 1993; 85: 704-10. 
De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the 
amyloid precursor protein. J Cell Sci, 2000; 113 ( Pt 11): 1857-70. 
del Rio-Hortega P. Art and artifice in the science of histology. 1933. Histopathology, 1933; 
22: 515-25. 
Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, 
Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced 
pluripotent stem cells generated from patients with ALS can be differentiated into 
motor neurons. Science, 2008; 321: 1218-21. 
Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma 
multiforme: a patient series. Ann Oncol, 2005; 16: 1702-8. 
Ebert AD, Svendsen CN. Human stem cells and drug screening: opportunities and 
challenges. Nat Rev Drug Discov, 2010; 9: 367-72. 
Ebert AD, Yu J, Rose FF, Jr., Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced 
pluripotent stem cells from a spinal muscular atrophy patient. Nature, 2009; 457: 
277-80. 
Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse 
embryos. Nature, 1981; 292: 154-6. 
Ferrer I, Sarmiento J. Nascent microglia in the developing brain. Acta Neuropathol, 1980; 50: 
61-7. 
Flugel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, Ellwart JW, Willem M, Lassmann 
H, Wekerle H. Migratory activity and functional changes of green fluorescent 
effector cells before and during experimental autoimmune encephalomyelitis. 
Immunity, 2001; 14: 547-60. 
Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. Normal adult ramified microglia 
separated from other central nervous system macrophages by flow cytometric 
sorting. Phenotypic differences defined and direct ex vivo antigen presentation to 
myelin basic protein-reactive CD4+ T cells compared. J Immunol, 1995; 154: 4309-
21. 
Giulian D, Baker TJ. Characterization of ameboid microglia isolated from developing 
mammalian brain. J Neurosci, 1986; 6: 2163-78. 
www.intechopen.com
 Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-Based Regenerative Medicine 
 
184 
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz 
E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate 
immune response to amyloid-beta. Nat Immunol, 2008; 9: 857-65. 
Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the 
normal and pathologic brain. Nat Neurosci, 2007; 10: 1387-94. 
Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. 
Silica crystals and aluminum salts activate the NALP3 inflammasome through 
phagosomal destabilization. Nat Immunol, 2008; 9: 847-56. 
Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA. Differential migration, LPS-
induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI 
cell lines and primary microglial cultures. J Neurochem, 2008; 107: 557-69. 
Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH. Expression of fractalkine (CX3CL1) 
and its receptor, CX3CR1, during acute and chronic inflammation in the rodent 
CNS. Glia, 2002; 37: 314-27. 
Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, 
Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of 
fractalkine receptor CX3CR1, which mediates both leukocyte migration and 
adhesion. Cell, 1997; 91: 521-30. 
Imamoto K, Leblond CP. Radioautographic investigation of gliogenesis in the corpus 
callosum of young rats. II. Origin of microglial cells. J Comp Neurol, 1978; 180: 139-
63. 
Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, 
Bauer A, Blesch A, Bogdahn U. Transforming growth factor-beta-mediated 
autocrine growth regulation of gliomas as detected with phosphorothioate 
antisense oligonucleotides. Int J Cancer, 1996; 65: 332-7. 
Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical 
prognostic factors in patients with glioblastoma multiforme treated with a 
combined modality approach. J Cancer Res Clin Oncol, 2003; 129: 477-84. 
Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein 
P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. 
Science, 1994; 265: 528-30. 
Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart 
M, Van Glabbeke M. Randomized trial on the efficacy of radiotherapy for cerebral 
low-grade glioma in the adult: European Organization for Research and Treatment 
of Cancer Study 22845 with the Medical Research Council study BRO4: an interim 
analysis. Int J Radiat Oncol Biol Phys, 2002; 52: 316-24. 
Kaur C, Hao AJ, Wu CH, Ling EA. Origin of microglia. Microsc Res Tech, 2001; 54: 2-9. 
Keles GE, Berger MS. Advances in neurosurgical technique in the current management of 
brain tumors. Semin Oncol, 2004; 31: 659-65. 
Kitamura T, Miyake T, Fujita S. Genesis of resting microglia in the gray matter of mouse 
hippocampus. J Comp Neurol, 1984; 226: 421-33. 
Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-
inflammatory macrophage phenotype in growth of human gliomas. J Pathol, 2008; 
216: 15-24. 
Krause M, Wohlfarth J, Georgi B, Pimentel N, Dorner D, Zips D, Eicheler W, Hessel F, Short 
SC, Joiner MC, Baumann M. Low-dose hyperradiosensitivity of human 
www.intechopen.com
Perspectives of Stem Cell-Derived Microglia for Medicine   
 
185 
glioblastoma cell lines in vitro does not translate into improved outcome of 
ultrafractionated radiotherapy in vivo. Int J Radiat Biol, 2005; 81: 751-8. 
Krauseneck P, Muller B. Chemotherapy of malignant gliomas. Recent Results Cancer Res, 
1994; 135: 135-47. 
Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott 
MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. Phase 
I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological 
and clinical results. J Clin Oncol, 2003; 21: 2508-18. 
Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain 
and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol, 2000; 18: 
675-9. 
Ling EA. Transformation of monocytes into amoeboid microglia in the corpus callosum of 
postnatal rats, as shown by labelling monocytes by carbon particles. J Anat, 1979; 
128: 847-58. 
Ling EA, Kaur C, Wong WC. Light and electron microscopic demonstration of non-specific 
esterase in amoeboid microglial cells in the corpus callosum in postnatal rats: a 
cytochemical link to monocytes. J Anat, 1982; 135: 385-94. 
Ling EA, Penney D, Leblond CP. Use of carbon labeling to demonstrate the role of blood 
monocytes as precursors of the 'ameboid cells' present in the corpus callosum of 
postnatal rats. J Comp Neurol, 1980; 193: 631-57. 
Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J. Bone-
marrow-derived cells contribute to the recruitment of microglial cells in response to 
beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol 
Dis, 2005; 18: 134-42. 
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in 
diverse forms of macrophage activation and polarization. Trends Immunol, 2004; 
25: 677-86. 
Mattson MP, Taub DD. Ancient viral protein enrages astrocytes in multiple sclerosis. Nat 
Neurosci, 2004; 7: 1021-3. 
Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, 
Bruck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6ChiCCR2+ 
monocytes only under defined host conditions. Nat Neurosci, 2007; 10: 1544-53. 
Miletic H, Fischer YH, Giroglou T, Rueger MA, Winkeler A, Li H, Himmelreich U, Stenzel 
W, Jacobs AH, von Laer D. Normal brain cells contribute to the bystander effect in 
suicide gene therapy of malignant glioma. Clin Cancer Res, 2007; 13: 6761-8. 
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes 
simplex virus-1 for the treatment of malignant gliomas. Nat Med, 1995; 1: 938-43. 
Nagai A, Mishima S, Ishida Y, Ishikura H, Harada T, Kobayashi S, Kim SU. Immortalized 
human microglial cell line: phenotypic expression. J Neurosci Res, 2005; 81: 342-8. 
Nagai A, Nakagawa E, Hatori K, Choi HB, McLarnon JG, Lee MA, Kim SU. Generation and 
characterization of immortalized human microglial cell lines: expression of 
cytokines and chemokines. Neurobiol Dis, 2001; 8: 1057-68. 
Napoli I, Kierdorf K, Neumann H. Microglial precursors derived from mouse embryonic 
stem cells. Glia, 2009; 57: 1660-71. 
Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience, 
2009; 158: 1030-8. 
www.intechopen.com
 Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-Based Regenerative Medicine 
 
186 
Neumann H. Microglia: a cellular vehicle for CNS gene therapy. J Clin Invest, 2006; 116: 
2857-60. 
Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic 
surveillants of brain parenchyma in vivo. Science, 2005; 308: 1314-8. 
Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, 
Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell, 
2008; 134: 877-86. 
Paterson JA, Privat A, Ling EA, Leblond CP. Investigation of glial cells in semithin sections. 
3. Transformation of subependymal cells into glial cells, as shown by 
radioautography after 3 H-thymidine injection into the lateral ventricle of the brain 
of young rats. J Comp Neurol, 1973; 149: 83-102. 
Perry VH, Hume DA, Gordon S. Immunohistochemical localization of macrophages and 
microglia in the adult and developing mouse brain. Neuroscience, 1985; 15: 313-26. 
Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, 
motility, angiogenesis, and immune escape. Microsc Res Tech, 2001; 52: 401-10. 
Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, 
Amadio S, Bergami A, Furlan R, Comi G, Vescovi AL, Martino G. Injection of adult 
neurospheres induces recovery in a chronic model of multiple sclerosis. Nature, 
2003; 422: 688-94. 
Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid beta-protein by 
a metalloprotease secreted by microglia and other neural and non-neural cells. J 
Biol Chem, 1997; 272: 6641-6. 
Rezaie P, Male D. Colonisation of the developing human brain and spinal cord by microglia: 
a review. Microsc Res Tech, 1999; 45: 359-82. 
Rezaie P, Male D. Mesoglia & microglia--a historical review of the concept of mononuclear 
phagocytes within the central nervous system. J Hist Neurosci, 2002; 11: 325-74. 
Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, Peterson PK. Role of 
microglia in central nervous system infections. Clin Microbiol Rev, 2004; 17: 942-64, 
table of contents. 
Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, 
Jachimczak P. Targeted tumor therapy with the TGF-beta 2 antisense compound 
AP 12009. Cytokine Growth Factor Rev, 2006; 17: 129-39. 
Scott EW, Mickle JP. Pediatric diencephalic gliomas--a review of 18 cases. Pediatr Neurosci, 
1987; 13: 225-32. 
Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central 
nervous system into fully differentiated parenchymal microglia. Faseb J, 2004; 18: 
998-1000. 
Smith AG. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol, 2001; 17: 
435-62. 
Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, Rogers D. Inhibition of 
pluripotential embryonic stem cell differentiation by purified polypeptides. Nature, 
1988; 336: 688-90. 
Soffietti R, Chio A, Giordana MT, Vasario E, Schiffer D. Prognostic factors in well-
differentiated cerebral astrocytomas in the adult. Neurosurgery, 1989; 24: 686-92. 
www.intechopen.com
Perspectives of Stem Cell-Derived Microglia for Medicine   
 
187 
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, 
Mitalipova M, Isacson O, Jaenisch R. Parkinson's disease patient-derived induced 
pluripotent stem cells free of viral reprogramming factors. Cell, 2009; 136: 964-77. 
Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper 
understanding of its pathogenesis reveals new targets for therapy. Annu Rev 
Neurosci, 2002; 25: 491-505. 
Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia, 2002; 40: 
133-9. 
Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid 
precursors mediate nervous tissue debris clearance and facilitate recovery in an 
animal model of multiple sclerosis. PLoS Med, 2007a; 4: e124. 
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction 
of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 
2007b; 131: 861-72. 
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell, 2006; 126: 663-76. 
Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG, Nishikawa S. Neuroepithelial 
cells supply an initial transient wave of MSC differentiation. Cell, 2007; 129: 1377-
88. 
Takata K, Kitamura Y, Yanagisawa D, Morikawa S, Morita M, Inubushi T, Tsuchiya D, 
Chishiro S, Saeki M, Taniguchi T, Shimohama S, Tooyama I. Microglial 
transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS 
Lett, 2007; 581: 475-8. 
Tsuchiya T, Park KC, Toyonaga S, Yamada SM, Nakabayashi H, Nakai E, Ikawa N, Furuya 
M, Tominaga A, Shimizu K. Characterization of microglia induced from mouse 
embryonic stem cells and their migration into the brain parenchyma. J 
Neuroimmunol, 2005; 160: 210-8. 
Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, 
Adany R, Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells 
are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type 
characteristics. J Leukoc Biol, 2008; 83: 1136-44. 
Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, 
Weiss EH, Melms A, Weller M. A functional role of HLA-G expression in human 
gliomas: an alternative strategy of immune escape. J Immunol, 2002; 168: 4772-80. 
Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf 
D, Nicola NA, Gough NM. Myeloid leukaemia inhibitory factor maintains the 
developmental potential of embryonic stem cells. Nature, 1988; 336: 684-7. 
Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, 
Ohgaki H, Aguzzi A, Rammensee HG, Weller M. Identification of CD70-mediated 
apoptosis of immune effector cells as a novel immune escape pathway of human 
glioblastoma. Cancer Res, 2002; 62: 2592-9. 
Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and 
cell therapy. Physiol Rev, 2005; 85: 635-78. 
Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A. T 
cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely 
related to transforming growth factor-beta. EMBO J, 1987; 6: 1633-6. 
www.intechopen.com
 Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-Based Regenerative Medicine 
 
188 
Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated 
major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked 
susceptibility to human autoimmune diseases. J Exp Med, 1995; 181: 1597-601. 
Yamanaka S. A fresh look at iPS cells. Cell, 2009; 137: 13-7. 
Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system 
immunity and glioma immunology. J Clin Neurosci, 2010; 17: 6-10. 
Yoshida S, Tanaka R. Generation of a human leukocyte antigen-A24-restricted antitumor 
cell with the use of SART-1 peptide and dendritic cells in patients with malignant 
brain tumors. J Lab Clin Med, 2004; 144: 201-7. 
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, 
Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA. Induced pluripotent 
stem cell lines derived from human somatic cells. Science, 2007; 318: 1917-20. 
Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo 
A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells 
ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 
Blood, 2005; 106: 1755-61. 
Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, 
Scholer HR, Duan L, Ding S. Generation of induced pluripotent stem cells using 
recombinant proteins. Cell Stem Cell, 2009; 4: 381-4. 
 
 
www.intechopen.com
Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-
Based Regenerative Medicine
Edited by Prof. Craig Atwood
ISBN 978-953-307-198-5
Hard cover, 410 pages
Publisher InTech
Published online 26, April, 2011
Published in print edition April, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Pluripotent stem cells have the potential to revolutionise medicine, providing treatment options for a wide
range of diseases and conditions that currently lack therapies or cures. This book describes recent advances
in the generation of tissue specific cell types for regenerative applications, as well as the obstacles that need to
be overcome in order to recognize the potential of these cells.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Kristin Roy, Clara Beutner and Harald Neumann (2011). Perspectives of Stem Cell-Derived Microglia for
Medicine, Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-Based Regenerative Medicine,
Prof. Craig Atwood (Ed.), ISBN: 978-953-307-198-5, InTech, Available from:
http://www.intechopen.com/books/embryonic-stem-cells-recent-advances-in-pluripotent-stem-cell-based-
regenerative-medicine/perspectives-of-stem-cell-derived-microglia-for-medicine
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
